# US 8,541,472 B2 · Antiseptic compositions, methods and systems

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,541,472 B2
- Document ID: US8541472B2
- Status: Granted
- Kind: B2
- Application number: 10/659,413
- Filed: 2003-09-10
- Published: 2004-06-10
- Granted: 2013-09-24
- Earliest claimed: 2001-12-05
- Assignees: Aseptica, Inc.
- Applicants: Peter Kite; David Hatton
- Inventors: Peter Kite; David Hatton
- Web page: https://patentgrep.com/patent/US8541472B2

## CPC

- A01N 37/44: containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
- A01N 25/02: containing liquids as carriers, diluents or solvents
- A01N 31/02: Acyclic compounds
- A01N 59/00: Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61L 2/18: Liquid substances
- A61L 29/16: Biologically active materials, e.g. therapeutic substances {(A61L29/048 takes precedence)}
- A61P 17/00: Drugs for dermatological disorders
- A61P 31/02: Local antiseptics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 33/04: Amoebicides
- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61L 2103/15: Laboratory, medical or dentistry appliances, e.g. catheters or sharps
- A61L 2202/11: Apparatus for generating biocidal substances, e.g. vaporisers, UV lamps
- A61L 2300/21: Acids
- A61L 2300/214: Amino acids
- A61L 2300/404: Biocides, antimicrobial agents, antiseptic agents
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Antiseptic compositions comprising at least one salt of EDTA are disclosed. These compositions have broad spectrum antimicrobial and antifungal activity and they also have anticoagulant properties. The antiseptic compositions have also demonstrated activity in penetrating and breaking down microbial slime, or biofilms. They are safe for human and medical uses and may be used as prophylactic preparations to prevent infection, or to reduce the proliferation of and/or eliminate existing or established infections.

## Claims

### Claim 1

A lock flush composition consisting essentially of at least one salt of ethylene diamine tetraacetic acid (EDTA) in solution, between 0.5% and 10% (v/v) ethanol and water, wherein the at least one salt is tetra-sodium ethylene diamine tetraacetic acid at a concentration of at least 1.5% (w/v) and less than 6.0% (w/v), wherein the lock flush composition has a pH greater than 9.5, wherein the lock flush composition is packaged in a sterile, non-pyrogenic form, and wherein the lock flush composition is biocompatible in a patient's bloodstream.

### Claim 2 (depends on 1)

A composition provided in a dry or partially hydrated formulation that, upon reconstitution with a solution, forms the lock flush composition of claim 1.